Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

CASTLE BIOSCIENCES INC

2024-Q2 EPS reported $0.22 revenue$159,976,000

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.
Raises FY2024 revenue guidance to $275-300M from prior $255-265M.
Adjusted EBITDA $21.5M vs ($5.3M) in Q2 2023; gross margin 81%.
Cash and investments $259.7M; net cash from operations $24.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.